Pharmacogenetics Flashcards
CYP2D6 Polymorphism
Debrisoquine effect–> excessive hypotension (increased concentrations and decreased metabolism of drug)
Ultrafast metabolism–> duplication of normal allele
Metabolizes 25% of prescription drugs
Anti-depressants
Metabolize codeine–> morphine
CYP2C19 Polymorphism
Poor metabolizer effect–> 3-20% are homozygous poor metab
PPI- omeprazole (poor metabolizer have higher drug levels, higher pH and better control of GERD)
Anti convulsants - Phenytoin (poor metabolizer with low therapeutic window causes more drug levels and side effects)
Anti-platelet–> Clopidogrel (activated by 2C19)
Even one slow allele causes increased outcomes of MI and stroke
By >50%
Clopidogrel and PPI
Both are substrates of CYP2C19
Competitive inhibition
Both are given post MI and Omeprazole causes decreased levels of activated Clopidogrel
Increased risk of serious CV event
CYP2C9 Polymorphism
Handles about 15% of drugs
Poor metabolizer phenotype *2 and *3 (31% of patients)
*1 is the wild type normal
Warfarin
Anticoagulant cleared exclusively by CYP2C9 (narrow therapeutic window)
*3 has a larger impact than *2
If *3 or *2 polymorphism
Significantly reduces warfarin clearance and increases half-life
Lower maintenance dose required
Increased risk of anti-coagulation/bleeding
Vitamin K Receptor (VKORC1) Polymorphism
VKORC1 is subunit of Vit K epoxide reductase and needed to take clotting factors for functional forms
Warfarin is antagonist of VKORC1 because competitive inhibitor
Polymorphism
Clade A–> H1 and H2 = lower expression of VKORC1 so lower warfarin dose needed
Clade B–> H7, H8, H9= higher expression of VKORC1 so higher warfarin dose needed
N-acetyltransferase-2
Detoxifies isoniazid (anti-tuberculosis drug)
Initial observation was increased neurological side effects
Correlation with plasma concentration and difference in plasma half-life
Autosomal-recessive trait
slow acetylators are homozygous for slow allele
Fast acetylators have one or two copies of fast allele
Pseudocholinesterase Polymorphism
Succinylcholine is a surgical muscle relaxant whose effects typically wear off 5 min after dose stopped
Atypical patients experience apnea and paralysis for 2-3 hours
May increase susceptibility to some insecticides and to cocaine toxicity
TPMT Polymorphism
Increased risk for life threatening bone marrow suppression when treated with 6-MP
Greater risk when TMPT activity decreases because it is used to clear the excess drug but now more active drug in bone marrow
Low activity allele has 2 SNPs in TPMT gene
SLCO1B1 Polymorphism
Organic anion transporter important for uptake of hydrophilic drugs into the liver
Statins decrease cholesterol by inactivating in liver but can’t get into liver so toxicity in blood
Skeletal muscle toxicity is the side effect (rhabdomyolysis, Myalgia, Myopathy)